ZA200605224B - Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions - Google Patents
Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositionsInfo
- Publication number
- ZA200605224B ZA200605224B ZA200605224A ZA200605224A ZA200605224B ZA 200605224 B ZA200605224 B ZA 200605224B ZA 200605224 A ZA200605224 A ZA 200605224A ZA 200605224 A ZA200605224 A ZA 200605224A ZA 200605224 B ZA200605224 B ZA 200605224B
- Authority
- ZA
- South Africa
- Prior art keywords
- estrogen
- days
- longer
- period
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03090405A EP1535618A1 (en) | 2003-11-26 | 2003-11-26 | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200605224B true ZA200605224B (en) | 2009-10-28 |
Family
ID=34443011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200605224A ZA200605224B (en) | 2003-11-26 | 2006-06-23 | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20080234240A1 (xx) |
| EP (3) | EP1535618A1 (xx) |
| JP (1) | JP2007512291A (xx) |
| KR (1) | KR20060126671A (xx) |
| CN (1) | CN1905885A (xx) |
| AR (1) | AR046671A1 (xx) |
| AU (1) | AU2004292778A1 (xx) |
| BR (1) | BRPI0416924A (xx) |
| CA (1) | CA2547051A1 (xx) |
| CR (1) | CR8450A (xx) |
| EA (1) | EA200600964A1 (xx) |
| EC (1) | ECSP066674A (xx) |
| GT (1) | GT200400242A (xx) |
| IL (1) | IL175858A0 (xx) |
| NO (1) | NO20062945L (xx) |
| PA (1) | PA8618301A1 (xx) |
| PE (1) | PE20051038A1 (xx) |
| RS (1) | RS20060348A (xx) |
| TW (1) | TW200529862A (xx) |
| UY (1) | UY28631A1 (xx) |
| WO (1) | WO2005051400A1 (xx) |
| ZA (1) | ZA200605224B (xx) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070111975A1 (en) * | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| DE102004062182B4 (de) * | 2004-12-20 | 2007-06-06 | Bayer Schering Pharma Ag | Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff |
| US20090181075A1 (en) * | 2005-07-15 | 2009-07-16 | Gordon Ryan D | Drospirenone containing transdermal drug delivery devices and methods of delivery thereof |
| EP1774970A1 (de) * | 2005-10-13 | 2007-04-18 | Bayer Schering Pharma AG | Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest |
| DE102005056527A1 (de) * | 2005-11-25 | 2007-07-12 | Grünenthal GmbH | Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels |
| WO2008018872A1 (en) * | 2006-08-10 | 2008-02-14 | Drugtech Corporation | Therapeutic methods of using estrogen compositions |
| EP1977752A1 (de) * | 2007-03-01 | 2008-10-08 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zubereitung zur Verminderung der Endometriose |
| DE102007011105A1 (de) * | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CN104546870B (zh) * | 2015-01-27 | 2018-01-12 | 唐凡兰 | 一种避孕药 |
| LT3106148T (lt) | 2015-06-18 | 2018-06-25 | Mithra Pharmaceuticals S.A. | Burnoje disperguojamos dozės vienetas, turintis estetrolio komponentą |
| TN2017000497A1 (en) | 2015-06-18 | 2019-04-12 | Mithra Pharmaceuticals S A | Orodispersible dosage unit containing an estetrol component |
| CN107750157B (zh) | 2015-06-18 | 2021-07-13 | 埃斯特拉私人有限责任公司 | 含雌四醇的口腔分散片剂 |
| ES2877186T3 (es) | 2015-06-18 | 2021-11-16 | Estetra Sprl | Comprimido orodispersable que contiene estetrol |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| JP2018083806A (ja) * | 2016-11-11 | 2018-05-31 | 持田製薬株式会社 | 月経困難症治療用組成物 |
| UA126746C2 (uk) * | 2018-02-07 | 2023-01-18 | Естетра Спрл | Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| CL2021001762A1 (es) * | 2021-07-01 | 2022-01-21 | Univ Pontificia Catolica Chile | Uso del estetrol como tratamiento para la endometriosis |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3969502A (en) * | 1972-04-14 | 1976-07-13 | Schering Aktiengesellschaft | Method for contraception by the administration of sequential contraceptive preparations |
| AU581486B2 (en) * | 1985-12-30 | 1989-02-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
| US5010070A (en) * | 1987-06-15 | 1991-04-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
| DK174724B1 (da) | 1986-07-15 | 2003-10-06 | Wyeth Corp | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet |
| US5276022A (en) * | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
| NZ226316A (en) * | 1987-09-24 | 1991-10-25 | Jencap Research Ltd | Pharmaceutical contraceptive preparations and packages containing from 20-35 unit dosages comprising an estrogen and a progestin; the unit dosages having alternating estrogen and progestin dominance |
| IE71203B1 (en) * | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
| DE4411585A1 (de) * | 1994-03-30 | 1995-10-05 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| DE19549264A1 (de) * | 1995-12-23 | 1997-06-26 | Schering Ag | Verfahren und Kit zur Kontrazeption |
| EP0921804B1 (en) * | 1996-07-26 | 2003-09-10 | Wyeth | Biphasic oral contraceptive method and kit comprising a combination of a progestin and estrogen |
| US6028064A (en) * | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
| DE19654609A1 (de) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder |
| US5898032A (en) * | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| ATE279198T1 (de) | 1997-08-27 | 2004-10-15 | Ortho Mcneil Pharm Inc | Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung |
| US20020193356A1 (en) * | 2001-05-23 | 2002-12-19 | Van Beek Agatha Antonia Magdalena | Means and method for hormonal contraception |
| JP2004521951A (ja) * | 2001-07-13 | 2004-07-22 | シエーリング アクチエンゲゼルシャフト | Ｈｒｔのためのドロスピレノン及びエストロゲンスルファメートの組み合わせ |
| US7320969B2 (en) | 2001-12-05 | 2008-01-22 | Duramed Pharmaceuticals, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
-
2003
- 2003-11-26 EP EP03090405A patent/EP1535618A1/en not_active Withdrawn
-
2004
- 2004-11-20 AU AU2004292778A patent/AU2004292778A1/en not_active Abandoned
- 2004-11-20 BR BRPI0416924-7A patent/BRPI0416924A/pt not_active IP Right Cessation
- 2004-11-20 CA CA002547051A patent/CA2547051A1/en not_active Abandoned
- 2004-11-20 RS YUP-2006/0348A patent/RS20060348A/sr unknown
- 2004-11-20 EP EP04803349A patent/EP1689409A1/en not_active Ceased
- 2004-11-20 EP EP08020987A patent/EP2044942A1/en not_active Withdrawn
- 2004-11-20 JP JP2006540407A patent/JP2007512291A/ja active Pending
- 2004-11-20 KR KR1020067012707A patent/KR20060126671A/ko not_active Application Discontinuation
- 2004-11-20 US US10/584,045 patent/US20080234240A1/en not_active Abandoned
- 2004-11-20 CN CNA2004800410231A patent/CN1905885A/zh active Pending
- 2004-11-20 WO PCT/EP2004/013545 patent/WO2005051400A1/en active Application Filing
- 2004-11-20 EA EA200600964A patent/EA200600964A1/ru unknown
- 2004-11-23 UY UY28631A patent/UY28631A1/es not_active Application Discontinuation
- 2004-11-25 GT GT200400242A patent/GT200400242A/es unknown
- 2004-11-25 PE PE2004001155A patent/PE20051038A1/es not_active Application Discontinuation
- 2004-11-25 PA PA20048618301A patent/PA8618301A1/es unknown
- 2004-11-26 AR ARP040104377A patent/AR046671A1/es not_active Application Discontinuation
- 2004-11-26 TW TW093136571A patent/TW200529862A/zh unknown
-
2006
- 2006-05-23 IL IL175858A patent/IL175858A0/en unknown
- 2006-06-13 CR CR8450A patent/CR8450A/es not_active Application Discontinuation
- 2006-06-23 EC EC2006006674A patent/ECSP066674A/es unknown
- 2006-06-23 ZA ZA200605224A patent/ZA200605224B/xx unknown
- 2006-06-23 NO NO20062945A patent/NO20062945L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1689409A1 (en) | 2006-08-16 |
| GT200400242A (es) | 2006-01-18 |
| IL175858A0 (en) | 2006-10-05 |
| WO2005051400A1 (en) | 2005-06-09 |
| JP2007512291A (ja) | 2007-05-17 |
| PE20051038A1 (es) | 2006-02-08 |
| CN1905885A (zh) | 2007-01-31 |
| UY28631A1 (es) | 2005-06-30 |
| EP1535618A1 (en) | 2005-06-01 |
| NO20062945L (no) | 2006-08-23 |
| AU2004292778A1 (en) | 2005-06-09 |
| ECSP066674A (es) | 2006-10-25 |
| RS20060348A (xx) | 2008-08-07 |
| BRPI0416924A (pt) | 2007-01-16 |
| EA200600964A1 (ru) | 2006-10-27 |
| TW200529862A (en) | 2005-09-16 |
| CR8450A (es) | 2007-06-06 |
| PA8618301A1 (es) | 2006-05-16 |
| AR046671A1 (es) | 2005-12-14 |
| CA2547051A1 (en) | 2005-06-09 |
| US20080234240A1 (en) | 2008-09-25 |
| KR20060126671A (ko) | 2006-12-08 |
| EP2044942A1 (en) | 2009-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200605224B (en) | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions | |
| HUP0202500A3 (en) | Use of a pharmaceutical combination of ethinylestradiol and drospirenone for producing pharmaceutical compositions having contraceptive activity | |
| HUP0302093A3 (en) | Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy | |
| HUP0301422A3 (en) | Pharmaceutical compositions of estrogenic agents | |
| HUP0203451A3 (en) | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation | |
| HUP0401250A3 (en) | Medical aerosol compositions and process for their preparation | |
| HK1082677A1 (en) | Androgen pharmaceutical composition and use for manufacture of medicament | |
| IL200482A0 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
| HUE043200T2 (hu) | Etinilösztradiol és klórmadinon-acetát kombinációját tartalmazó hormonális fogamzágátló | |
| EP1648474A4 (en) | PROCESS AND PHARMACEUTICAL COMPOSITIONS FOR WOUND HEALING | |
| ZA200700483B (en) | Process for the preparation 2-substituted-derivatives of estrone and estradiol | |
| HUP0302130A3 (en) | Combination pharmaceutical compositions and process for their preparation | |
| HUP0301460A3 (en) | Use of antiprogestins for producing pharmaceutical compositions for prohylaxis and treatment of hormone-dependent diseases | |
| IL173148A0 (en) | Methods and pharmaceutical compositions for healing wounds | |
| HUP0303731A3 (en) | Sulfonylguanidines and their use for preparation of pharmaceutical compositions | |
| HUP0300626A3 (en) | Use of progestogen and mifepristone for preparation of anticancer pharmaceutical compositions | |
| HUP0301317A3 (en) | Use of neuroprotective 7-beta-hydroxysteroids for preparation of pharmaceutical compositions | |
| HUP0203032A3 (en) | Eplerenone crystalline form exhibiting enhanced dissolution rate, process for their preparation and pharmaceutical compositions containing them and their use | |
| EP1807122A4 (en) | MEDICAL AEROSOL FORMULATIONS AND METHOD FOR SYNTHETIZING INGREDIENTS THEREFOR | |
| EP1857111A3 (en) | Composition comprising a combination of an aromatase inhibitor, a progestin and an estrogen, and its use for the treatment of endometriosis | |
| PL357020A1 (en) | Pharmaceutical compositions containing steroidal structures and uses thereof | |
| HUP0301134A3 (en) | Use of 7-hydroxyepiandrosterone having neuroprotective activity for preparing pharmaceutical compositions | |
| IL162101A (en) | Crystalline form of a ribofuranosyluronamide derivative, pharmaceutical compositions comprising it, processes for its preparation and use thereof in the preparation of medicaments | |
| AU2002239417A1 (en) | Diagnostic and therapeutic compositions and methods related to anaphylatoxin c3a receptor | |
| HUP0200311A3 (en) | Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions |